On October 5, 2026, GE HealthCare agreed to buy SOFIE Biosciences from Trilantic North America for $945 million in cash, with the deal expected to close in the first half of 2027. SOFIE is a contract manufacturer of PET radiopharmaceuticals with 15 sites across the United States, 21 cyclotrons and one site focused on theranostics, and the sale includes U.S. rights to a Phase III cancer-imaging tracer called FAPI-74. [1][2] GE calls the purchase a "final mile" footprint for PET radiopharmaceutical supply. [1]
The reason is physics. According to GE's release, fluorine-18, the isotope behind most PET tracers, has a half-life of about 110 minutes, which makes proximity to patients essential. [1] A tracer made in the wrong place is half gone before it arrives.
The claim of this piece is that when a product decays in under two hours, location is the asset. The molecule can be licensed, copied or improved; a cyclotron within reach of the scanner cannot be shipped in from far away. In that kind of business, a network of sites is what a buyer pays for, and $945 million for 15 of them says what that is worth.
The other side of the same fact is access. A national study of Medicare claims for nearly 500,000 men newly diagnosed with prostate cancer between 2019 and 2021 found PET imaging in 8.4 percent of men in metropolitan counties, 7.3 percent in urban counties and 7.2 percent in rural counties. Rural Black men were the least likely to be scanned, with odds 0.69 times those of their metropolitan counterparts. [3] The authors point to limited access to specialized scanners and radioactive tracers. [3] A 2025 systematic review of 166 studies reached a similar conclusion, finding disparities in PET access along racial, socioeconomic and geographic lines. [4]
The rural base those studies describe is still thinning. Chartis, a health-care research firm, counts 206 rural hospitals that have closed or converted to models without inpatient care since 2010, 448 that have stopped offering chemotherapy, and 417 more it calls vulnerable to closure. It estimates a 15 percent cut in Medicaid reimbursement would cost rural hospitals more than $1.8 billion. [5] A scan needs a scanner, a tracer and a facility that stays open to host them.
Those studies show the pattern, not its cause, and they say nothing about SOFIE. In my reading, a network built where the volume is will serve where the volume is, so whether this acquisition widens or narrows access depends on where the next sites go. GE's announcement does not say. That is my interpretation, not a finding.
For an investor, a business whose product decays has a different moat: sites, licenses and volume within reach. Ask what happens to a tracer whose volume cannot justify a cyclotron inside 110 minutes of the patient.
Related: The Door and the Gate, on who may reach private markets; 700 Rural Hospitals Are Now at Risk of Closing.
Sources
- GE HealthCare to Acquire SOFIE Biosciences, Establishing a "Final Mile" Footprint for PET Radiopharmaceutical Supply in the U.S., GE HealthCare release via BioSpace, October 5, 2026
- GE HealthCare to Acquire SOFIE Biosciences for $945 Million, Pulse 2.0
- Rural Patients Less Likely to Receive Advanced PET Imaging for Prostate Cancer, National Study Finds, Applied Radiation Oncology
- Barriers to Equitable Access: A Systematic Examination of PET/CT Imaging Disparities, Journal of Nuclear Medicine, June 2025
- 2026 Rural Health State of the State, Chartis
The deal terms, network size and half-life statement are GE HealthCare's own, as carried in its release and trade reports; the sale is expected to close in the first half of 2027 subject to approvals. The prostate-cancer study is described through a trade publication's report of it, the Chartis figures are the firm's own estimates, and the reading that location is the asset and that siting will decide access is the author's interpretation. This is not medical or investment advice.